FindTrial
Sign In

efficacy of treatment with bevacizumab,in the macular degeneration. - ND

efficacy of treatment with bevacizumab,in the macular degeneration. - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-001418-17-IT
Enrollment
Unknown
Registered
2007-03-29
Start date
2007-11-25
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular degeneretion aging dependent. MedDRA version: 9.1 Level: LLT Classification code 10025409 Term: Macular degeneration

Interventions

Trade Name: AVASTIN Pharmaceutical Form: Solution for injection INN or Proposed INN: BEVACIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-

Sponsors

AZIENDA OSPEDALIERA DI PADOVA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients whit eging of 50 years affected of maculopatia. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: other cause of maculo patia.non eging.

Design outcomes

Primary

MeasureTime frame
Main Objective: valutation of the efficacy of bevacizumab intravitreal somministrate of only orPTD.;Secondary Objective: valutation bevacizumabused only or whit therapy PTD.riducethe n PTD.;Primary end point(s): valutation the efficacy of bevacizumab.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026